Article

Gene mutation protects against dry AMD

Gene mutation protects against dry AMD

Lexington, KY-Researchers have identified a link between toll-like receptor 3 (TLR3), a protein that alerts the body's immune system to infections and, the dry form of age-related macular degeneration (AMD) and will report their results in the online edition of the New England Journal of Medicine.

"This is yet another breakthrough in our continuing appreciation that AMD is a genetic disease," said Philip Rosenfeld, MD, PhD, a professor of ophthalmology at the Bascom Palmer Eye Institute at the University of Miami. He was not involved in the study.

A mutated form of TLR3 protects against dry AMD, and when TLR3 is activated it causes infected cells to die. "If you have this mutation, your TLR3 gene doesn't work properly," Jayakrishna Ambati, MD, a retinal surgeon in University of Kentucky's Department of Ophthalmology and Visual Sciences. "These people are protected."

Dr. Rosenfeld said that it was premature to assume that short-interfering RNAs, as the drugs are called, would predispose people to dry AMD. The risk should be tracked but it doesn't negate the potential of the drugs, he said.

"We must await the study results before jumping to any conclusions," said Dr. Rosenfeld, who is doing phase I clinical trials for an siRNA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.